Bextra Withdrawal Costs Pfizer $1.28 Bil. In First Quarter
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer will have to take charges to write off assets relating to the withdrawal of the COX-2 inhibitor in addition to $71 mil. in expected product returns. Pfizer has revised its April 5 guidance downward to reflect the withdrawal.